# Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)

> **NCT03527147** · PHASE1 · COMPLETED · sponsor: **Acerta Pharma BV** · enrollment: 30 (actual)

## Conditions studied

- NHL
- DLBCL
- Non-hodgkin's Lymphoma
- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** AZD9150
- **DRUG:** Acalabrutinib
- **DRUG:** AZD6738
- **DRUG:** Hu5F9-G4
- **DRUG:** Rituximab
- **DRUG:** AZD5153

## Key facts

- **NCT ID:** NCT03527147
- **Lead sponsor:** Acerta Pharma BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-19
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-03-31
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-08-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03527147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03527147, "Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03527147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*